- Home
- NAAS vs CYCN Comparison
NAAS vs CYCN Comparison
Compare NAAS & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAAS
- CYCN
- Stock Information
- Founded
- NAAS 2019
- CYCN 2018
- Country
- NAAS China
- CYCN United States
- Employees
- NAAS N/A
- CYCN N/A
- Industry
- NAAS Other Specialty Stores
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- NAAS Consumer Discretionary
- CYCN Health Care
- Exchange
- NAAS Nasdaq
- CYCN Nasdaq
- Market Cap
- NAAS 9.2M
- CYCN 7.6M
- IPO Year
- NAAS 2017
- CYCN N/A
- Fundamental
- Price
- NAAS $3.70
- CYCN $2.53
- Analyst Decision
- NAAS
- CYCN
- Analyst Count
- NAAS 0
- CYCN 0
- Target Price
- NAAS N/A
- CYCN N/A
- AVG Volume (30 Days)
- NAAS 81.7K
- CYCN 1.1M
- Earning Date
- NAAS 11-19-2025
- CYCN 11-13-2025
- Dividend Yield
- NAAS N/A
- CYCN N/A
- EPS Growth
- NAAS N/A
- CYCN N/A
- EPS
- NAAS N/A
- CYCN N/A
- Revenue
- NAAS $27,534,354.00
- CYCN $2,174,000.00
- Revenue This Year
- NAAS $378.49
- CYCN N/A
- Revenue Next Year
- NAAS N/A
- CYCN N/A
- P/E Ratio
- NAAS N/A
- CYCN N/A
- Revenue Growth
- NAAS N/A
- CYCN N/A
- 52 Week Low
- NAAS $1.96
- CYCN $1.27
- 52 Week High
- NAAS $68.16
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- NAAS 52.72
- CYCN 50.11
- Support Level
- NAAS $3.59
- CYCN $2.17
- Resistance Level
- NAAS $4.11
- CYCN $2.59
- Average True Range (ATR)
- NAAS 0.34
- CYCN 0.33
- MACD
- NAAS -0.08
- CYCN -0.01
- Stochastic Oscillator
- NAAS 11.04
- CYCN 23.53
About NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.